<div id="readability-page-1"><div>                     <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/adaptive-biotechnologies-co-logo-1200x675.png/query-dj0yMDI0MDUyMjEzMjgwNQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1200" height="675" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/adaptive-biotechnologies-co-logo-1200x675.png/query-dj0yMDI0MDUyMjEzMjgwNQ"/>Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) CFO Kyle Piskel sold 3,115 shares of the firm's stock in a transaction on Monday, May 18th. The shares were sold at an average price of $13.04, for a total value of $40,619.60. Following the completion of the sale, the chief financial officer directly owned 256,725 shares in the company, valued at approximately $3,347,694. This represents a 1.20% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.</p><p>Kyle Piskel also recently made the following trade(s): </p><ul><li>On Wednesday, March 11th, Kyle Piskel sold 18,672 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.17, for a total value of $245,910.24. </li></ul><h2>Adaptive Biotechnologies Stock Performance</h2><p>Shares of ADPT stock opened at $13.96 on Thursday. The stock's fifty day moving average price is $13.81 and its two-hundred day moving average price is $15.65. The company has a market cap of $2.23 billion, a PE ratio of -42.30 and a beta of 2.16. Adaptive Biotechnologies Corporation has a fifty-two week low of $8.50 and a fifty-two week high of $20.76. </p><hr/><hr/><p>Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.16) by $0.03. The firm had revenue of $70.87 million for the quarter, compared to the consensus estimate of $61.03 million. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The company's revenue was up 35.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.20) EPS.  On average, equities analysts predict that  Adaptive Biotechnologies Corporation will post -0.48 EPS for the current fiscal year. </p><h2>Analyst Ratings Changes</h2><p>A number of brokerages have recently commented on ADPT. Piper Sandler  set a $21.00 price target on Adaptive Biotechnologies in a research note on Friday, February 6th. Wall Street Zen cut Adaptive Biotechnologies from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, March 7th. Morgan Stanley dropped their price target on Adaptive Biotechnologies from $21.00 to $18.00 and set an &#34;equal weight&#34; rating for the company in a research note on Tuesday, May 12th. Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of Adaptive Biotechnologies in a research note on Monday, April 20th. Finally, BTIG Research  reiterated a &#34;buy&#34; rating and issued a $22.00 price target on shares of Adaptive Biotechnologies in a research note on Wednesday, May 6th. Six investment analysts have rated the stock with a Buy rating, one  has issued  a Hold rating and one  has issued  a Sell rating to the company. Based on data from MarketBeat.com, Adaptive Biotechnologies presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $19.57.</p><p><b>Get Our Latest Analysis on ADPT</b></p><h2>Institutional Inflows and Outflows</h2><p>Large investors have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd bought a new position in shares of  Adaptive Biotechnologies in the 4th quarter valued at $28,000.  EverSource Wealth Advisors LLC raised its position in  Adaptive Biotechnologies by 197.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company's stock worth $38,000 after purchasing an additional 1,565 shares during the last quarter.  Assetmark Inc. raised its position in  Adaptive Biotechnologies by 867.9% during the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company's stock worth $49,000 after purchasing an additional 2,708 shares during the last quarter.  T. Rowe Price Investment Management Inc. bought a new position in  Adaptive Biotechnologies during the 4th quarter worth $51,000.  Finally, Strive Financial Group LLC bought a new position in  Adaptive Biotechnologies during the 4th quarter worth $52,000. 99.17% of the stock is currently owned by institutional investors. </p><h2>About Adaptive Biotechnologies</h2><p> (Get Free Report)</p><p>Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.  </p><p>The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Adaptive Biotechnologies</li><li>The Palantir Paradox—Record Numbers and a Stock That Won't Cooperate</li><li>TJX Companies Fires on All Cylinders With 9% Revenue Growth</li><li>From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook</li><li>AI Consolidation Begins: Blackstone &amp; Google Forge an AI Empire</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QURQVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QURQVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].</em></p>                     <div>                         <p>Insider Buying or Selling at Adaptive Biotechnologies?</p>                         <p>Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Adaptive Biotechnologies and related companies.</p>                                                                       </div>                                                               <div>                         <p>From Our Partners</p><div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260220101326_pushjb4-before.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260220101326_pushjb4-before.png"/></p><div><p>SpaceX eyes a 1.75 trillion valuation - here's what to know</p><p>Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...</p><p><span>Brownstone Research</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODk0OA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODk0OA"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.advantagegold.com/wp-content/uploads/2025/05/trump-2-0-1.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="400" height="593" original-src="https://imageproxy.pbkrs.com/https://www.advantagegold.com/wp-content/uploads/2025/05/trump-2-0-1.png"/></p><div><p>Iran's New Leader Just Said Something That Should Terrify Every American</p><p>Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...</p><p><span>American Alternative</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODkwMg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODkwMg"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260204150656_pushelon-6083103640.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260204150656_pushelon-6083103640.jpg"/></p><div><p>$30 stock to buy before Starlink goes public (WATCH NOW!)</p><p>In the next 3 minutes…  James Altucher – legendary investor and venture capitalist…  And someone who’s kno...</p><p><span>Paradigm Press</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODEzNg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODEzNg"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260413094022_pushgold-bullion-163553640.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260413094022_pushgold-bullion-163553640.jpg"/></p><div><p>Trump's gold order: the announcement they won't put on the front page</p><p>On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...</p><p><span>Reagan Gold Group</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTA5MQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTA5MQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://assets.stansberryresearch.com/uploads/sites/4/2026/03/Screenshot-2026-03-24-150248-1.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="250" height="250" original-src="https://imageproxy.pbkrs.com/https://assets.stansberryresearch.com/uploads/sites/4/2026/03/Screenshot-2026-03-24-150248-1.png"/></p><div><p>My feud with Zohran Mamdani</p><p>Emmy-winning analyst releases his next big story  Whitney Tilson shocked the nation on 60 Minutes when he ac...</p><p><span>Stansberry Research</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODU5Mg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODU5Mg"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://files.admin.sovereignsociety.com/images/lies-450.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="450" height="156" original-src="https://imageproxy.pbkrs.com/https://files.admin.sovereignsociety.com/images/lies-450.png"/></p><div><p>Iran War Shock: What I Was Told In That Private Meeting</p><p>You’re Being LIED To About The Iran War  Forget EVERYTHING you’ve heard about the Iran war.  Especially th...</p><p><span>Banyan Hill Publishing</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODcyOQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODcyOQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260406130341_pushstock-market-6695489640.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260406130341_pushstock-market-6695489640.jpg"/></p><div><p>Why this tiny stock may move before the SpaceX IPO drops</p><p>The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...</p><p><span>Behind the Markets</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODk2Ng?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODk2Ng"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260512161034_pushlaptop-1839876640.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260512161034_pushlaptop-1839876640.jpg"/></p><div><p>Your book attached</p><p>Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...</p><p><span>Profits Run</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTQ0OQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTQ0OQ"/></p></div></div></div>                     </div>                 </div></div>

ADPT

<p>Adaptive Biotechnologies CFO Kyle Piskel sold 3,115 shares at $13.04 each, totaling $40,619.60, reducing his ownership by 1.20% to 256,725 shares. The sale was to cover tax obligations from equity awards. The company reported a revenue increase of 35.1% year-over-year, with a negative EPS of ($0.13) for the last quarter. Analysts have mixed ratings on the stock, with a consensus price target of $19.57.</p>

Market Beat

Adaptive Biotechnologies

Piper Sandler Cos

Morgan Stanley

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Adaptive Biotechnologies (NASDAQ:ADPT) CFO Sells $40,619.60 in Stock